SI3342411T1 - Derivat rapamicina za zdravljenje raka trebušne slinavke - Google Patents
Derivat rapamicina za zdravljenje raka trebušne slinavkeInfo
- Publication number
- SI3342411T1 SI3342411T1 SI200231097T SI200231097T SI3342411T1 SI 3342411 T1 SI3342411 T1 SI 3342411T1 SI 200231097 T SI200231097 T SI 200231097T SI 200231097 T SI200231097 T SI 200231097T SI 3342411 T1 SI3342411 T1 SI 3342411T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pancreas cancer
- rapamycin derivative
- treating pancreas
- treating
- rapamycin
- Prior art date
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title 1
- 208000008443 pancreatic carcinoma Diseases 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0104072A GB0104072D0 (en) | 2001-02-19 | 2001-02-19 | Organic compounds |
GB0124957A GB0124957D0 (en) | 2001-10-17 | 2001-10-17 | Organic compounds |
EP18155724.0A EP3342411B1 (en) | 2001-02-19 | 2002-02-18 | Rapamycin derivative for treating pancreas cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SI3342411T1 true SI3342411T1 (sl) | 2019-10-30 |
Family
ID=26245731
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200231056T SI2269603T1 (sl) | 2001-02-19 | 2002-02-18 | Zdravljenje tumorjev dojke s rapamicinskim derivatom v kombinaciji z ekstemestanom |
SI200231097T SI3342411T1 (sl) | 2001-02-19 | 2002-02-18 | Derivat rapamicina za zdravljenje raka trebušne slinavke |
SI200231088A SI2762140T1 (sl) | 2001-02-19 | 2002-02-18 | Zdravljenje trdnih možganskih tumorjev z derivatom rapamicina |
SI200231092T SI3143995T1 (sl) | 2001-02-19 | 2002-02-18 | Derivat rapamicina za zdravljenje pljučnega raka |
SI200231094T SI3351246T1 (sl) | 2001-02-19 | 2002-02-18 | Derivat rapamicina za zdravljenje trdnega tumorja, povezanega z deregulirano angiogenezo |
SI200231078A SI2269604T1 (sl) | 2001-02-19 | 2002-02-18 | Zdravljenje solidnih tumorjev ledvic z rapamicinskim derivatom |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200231056T SI2269603T1 (sl) | 2001-02-19 | 2002-02-18 | Zdravljenje tumorjev dojke s rapamicinskim derivatom v kombinaciji z ekstemestanom |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200231088A SI2762140T1 (sl) | 2001-02-19 | 2002-02-18 | Zdravljenje trdnih možganskih tumorjev z derivatom rapamicina |
SI200231092T SI3143995T1 (sl) | 2001-02-19 | 2002-02-18 | Derivat rapamicina za zdravljenje pljučnega raka |
SI200231094T SI3351246T1 (sl) | 2001-02-19 | 2002-02-18 | Derivat rapamicina za zdravljenje trdnega tumorja, povezanega z deregulirano angiogenezo |
SI200231078A SI2269604T1 (sl) | 2001-02-19 | 2002-02-18 | Zdravljenje solidnih tumorjev ledvic z rapamicinskim derivatom |
Country Status (27)
Country | Link |
---|---|
US (10) | US8410131B2 (sl) |
EP (11) | EP2269604B1 (sl) |
JP (14) | JP2004525899A (sl) |
KR (3) | KR20050095906A (sl) |
CN (5) | CN104274442A (sl) |
AU (1) | AU2002250968C1 (sl) |
BR (1) | BR0207378A (sl) |
CA (3) | CA2438504C (sl) |
CY (11) | CY1116616T1 (sl) |
CZ (5) | CZ303611B6 (sl) |
DK (6) | DK3351246T3 (sl) |
ES (8) | ES2705016T3 (sl) |
HK (7) | HK1146245A1 (sl) |
HU (1) | HUP0303271A3 (sl) |
IL (13) | IL157425A0 (sl) |
LT (9) | LT2762140T (sl) |
LU (3) | LU92880I2 (sl) |
MX (3) | MXPA03007418A (sl) |
NO (14) | NO333105B1 (sl) |
NZ (1) | NZ527692A (sl) |
PL (5) | PL363918A1 (sl) |
PT (7) | PT2762140T (sl) |
RU (8) | RU2322981C2 (sl) |
SI (6) | SI2269603T1 (sl) |
SK (5) | SK288545B6 (sl) |
TW (2) | TW200626151A (sl) |
WO (1) | WO2002066019A2 (sl) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Corporation | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
CN104274442A (zh) | 2001-02-19 | 2015-01-14 | 诺华股份有限公司 | 癌症的治疗 |
IL158800A0 (en) * | 2001-06-01 | 2004-05-12 | Wyeth Corp | Antineoplastic combinations |
JP4636486B2 (ja) | 2002-02-11 | 2011-02-23 | バイエル、ファーマシューテイカルズ、コーポレイション | 脈管形成阻害活性を有するアリール尿素 |
US8383605B2 (en) * | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
JP2005535688A (ja) * | 2002-07-30 | 2005-11-24 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用 |
US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
WO2004032923A1 (en) * | 2002-10-11 | 2004-04-22 | Dana-Farber Cancer Institute Inc | Epothilone derivatives for the treatment of multiple myeloma |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
ATE366108T1 (de) | 2003-05-20 | 2007-07-15 | Bayer Pharmaceuticals Corp | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
PL1663978T3 (pl) | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
CN1957092B (zh) * | 2004-02-23 | 2013-04-03 | 诺瓦提斯公司 | P53野生型作为使用与细胞毒剂组合的mTOR抑制剂治疗的生物标志 |
GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
US20080113039A1 (en) * | 2004-03-23 | 2008-05-15 | Stephen Robert Wedge | Combination Therapy |
BRPI0608152A2 (pt) | 2005-02-09 | 2009-11-10 | Macusight Inc | formulações para tratamento ocular |
WO2006094385A1 (en) * | 2005-03-07 | 2006-09-14 | Robarts Research Institute | Use of a combination of myxoma virus and rapamycin for therapeutic treatment |
GB0504995D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Use of a compound |
US20100061994A1 (en) * | 2005-03-11 | 2010-03-11 | Rose Mary Sheridan | Medical uses of 39-desmethoxyrapamycin and analogues thereof |
GB0504994D0 (en) * | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
GB0507918D0 (en) | 2005-04-19 | 2005-05-25 | Novartis Ag | Organic compounds |
KR20130087058A (ko) * | 2005-07-20 | 2013-08-05 | 노파르티스 아게 | 피리미딜아미노벤즈아미드와 mtor 키나제 억제제의 조합물 |
EP1962839A4 (en) | 2005-11-14 | 2010-08-25 | Ariad Pharma Inc | ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER |
PL2275103T3 (pl) * | 2005-11-21 | 2014-09-30 | Novartis Ag | Inhibitory mTOR w leczeniu nowotworów neuroendokrynnych |
PT1983984T (pt) | 2006-02-02 | 2018-06-14 | Novartis Ag | Tratamento da esclerosa tuberosa |
GB0602123D0 (en) * | 2006-02-02 | 2006-03-15 | Novartis Ag | Organic compounds |
WO2007092620A2 (en) | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
PL2001466T3 (pl) | 2006-03-23 | 2016-06-30 | Santen Pharmaceutical Co Ltd | Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń |
US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
US20080085874A1 (en) * | 2006-08-28 | 2008-04-10 | The Regents Of The University Of California | Small molecule potentiator of hormonal therapy for breast cancer |
US9820888B2 (en) | 2006-09-26 | 2017-11-21 | Smith & Nephew, Inc. | Wound dressing |
KR101943230B1 (ko) * | 2007-03-07 | 2019-01-28 | 아브락시스 바이오사이언스, 엘엘씨 | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
CN101292980B (zh) * | 2007-04-28 | 2010-11-10 | 上海交通大学医学院附属仁济医院 | 一种含有雷帕霉素的用于治疗大肠癌的药物组合物 |
JP2010536738A (ja) * | 2007-08-16 | 2010-12-02 | バイオコンパティブルズ ユーケー リミテッド | 薬剤の組み合わせの送達 |
US20090149511A1 (en) * | 2007-10-30 | 2009-06-11 | Syndax Pharmaceuticals, Inc. | Administration of an Inhibitor of HDAC and an mTOR Inhibitor |
WO2009126965A2 (en) * | 2008-04-11 | 2009-10-15 | The Regents Of The University Of Colorado | Compositions, methods and uses for modulations of brca1 |
AU2009279806B2 (en) * | 2008-08-04 | 2015-04-30 | Five Prime Therapeutics, Inc. | FGFR extracellular domain acidic region muteins |
GB0902368D0 (en) | 2009-02-13 | 2009-04-01 | Smith & Nephew | Wound packing |
GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
US8791315B2 (en) | 2010-02-26 | 2014-07-29 | Smith & Nephew, Inc. | Systems and methods for using negative pressure wound therapy to manage open abdominal wounds |
CA2794513A1 (en) | 2010-03-31 | 2011-10-06 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
PE20140230A1 (es) | 2010-08-20 | 2014-02-26 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3) |
UY34487A (es) | 2011-12-05 | 2013-07-31 | Novartis Ag | Anticuerpos para receptor de factor de crecimiento epidérmico 3(her3) |
AU2013264934B2 (en) | 2012-05-23 | 2017-07-20 | Smith & Nephew Plc | Apparatuses and methods for negative pressure wound therapy |
CA3178997A1 (en) | 2012-08-01 | 2014-02-06 | Smith & Nephew Plc | Wound dressing |
CN104661626B (zh) | 2012-08-01 | 2018-04-06 | 史密夫及内修公开有限公司 | 伤口敷料 |
WO2014140606A1 (en) | 2013-03-15 | 2014-09-18 | Smith & Nephew Plc | Wound dressing and method of treatment |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
WO2016066608A1 (en) | 2014-10-28 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging |
CN108371711A (zh) * | 2015-08-17 | 2018-08-07 | 库拉肿瘤学公司 | 使用法尼基转移酶抑制剂治疗癌症患者的方法 |
MX2018011101A (es) * | 2016-03-15 | 2018-11-22 | Tyme Inc | Composiciones farmaceuticas para el tratamiento del cancer. |
WO2018100190A1 (en) | 2016-12-02 | 2018-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for diagnosing renal cell carcinoma |
US11584733B2 (en) | 2017-01-09 | 2023-02-21 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
EP4046989A1 (en) | 2017-01-09 | 2022-08-24 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
EP3644914A1 (en) | 2017-06-30 | 2020-05-06 | T J Smith & Nephew Limited | Negative pressure wound therapy apparatus |
WO2019089556A1 (en) * | 2017-10-31 | 2019-05-09 | Steve Gorlin | Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof |
US11407723B2 (en) | 2018-01-09 | 2022-08-09 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
WO2019212991A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mtor inhibitors |
JP7358387B2 (ja) | 2018-05-01 | 2023-10-10 | レヴォリューション・メディスンズ,インコーポレイテッド | Mtor阻害剤としてのc40-、c28-およびc-32-連結ラパマイシン類似体 |
CN108825638A (zh) * | 2018-08-01 | 2018-11-16 | 安徽送变电工程有限公司 | 一种应用于螺纹工件的防盗装置 |
GB201905780D0 (en) | 2019-04-25 | 2019-06-05 | La Thangue Nicholas | Cancer therapy |
BR112021022784A2 (pt) | 2019-05-14 | 2022-03-22 | Tyme Inc | Composições e métodos para tratamento do câncer |
US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
KR20230053539A (ko) | 2021-10-14 | 2023-04-21 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US876165A (en) | 1904-05-11 | 1908-01-07 | George K Woodworth | Wireless telegraph transmitting system. |
GB104072A (en) | 1916-04-14 | 1917-02-22 | William Henry Nosworthy | Apparatus for Lighting Fires or Heating or other purposes. |
GB124957A (en) | 1918-06-04 | 1919-04-10 | Frederick William Miller | Improvement in Glass Moulding. |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US4885171A (en) * | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
BE877700A (fr) * | 1978-11-03 | 1980-01-14 | Ayerst Mckenna & Harrison | Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes |
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
LU88769I2 (fr) | 1982-07-23 | 1996-11-05 | Zeneca Ltd | Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R)) |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
IL86632A0 (en) | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
JP3140228B2 (ja) * | 1992-02-17 | 2001-03-05 | ファイザー製薬株式会社 | 新規な大環状ラクトンおよびその生産菌 |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (sl) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5256790A (en) * | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
GB9221220D0 (en) * | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
WO1994009019A1 (en) | 1992-10-14 | 1994-04-28 | Unichema Chemie B.V. | Process for the preparation of alkylglycosides |
ES2278663T3 (es) | 1992-10-28 | 2007-08-16 | Genentech, Inc. | Antagonistas del factor de crecimiento de celulas endoteliales vasculares vegf. |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
DE4301781C2 (de) | 1993-01-23 | 1995-07-20 | Lohmann Therapie Syst Lts | Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
US5387680A (en) * | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
GB9325400D0 (en) | 1993-12-11 | 1994-02-16 | Sarll David P G | Temperature recorder |
EP0734389B1 (en) | 1993-12-17 | 2000-03-29 | Novartis AG | Rapamycin derivatives useful as immunosuppressants |
WO1995028156A1 (en) * | 1994-04-14 | 1995-10-26 | Sepracor, Inc. | Treating estrogen-dependent diseases with (-)-fadrozole |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
GB9417873D0 (en) | 1994-09-06 | 1994-10-26 | Sandoz Ltd | Organic compounds |
IL129547A (en) | 1994-10-26 | 2001-01-11 | Novartis Ag | Pharmaceutical compositions comprising a macrolide and an acid |
ES2332984T3 (es) | 1995-03-30 | 2010-02-16 | Pfizer Products Inc. | Derivados de quinazolinas. |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
DE69624921T2 (de) * | 1995-06-09 | 2003-09-11 | Novartis Ag | Rapamycinderivate |
DK0836605T3 (da) | 1995-07-06 | 2002-05-13 | Novartis Ag | Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling |
US5567831A (en) * | 1995-08-16 | 1996-10-22 | Duguesne University Of The Holy Ghost | Non-steroidal sulfatase inhibitor compounds and their method of use |
DE19544507B4 (de) * | 1995-11-29 | 2007-11-15 | Novartis Ag | Cyclosporin enthaltende Präparate |
GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9606452D0 (en) * | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
NZ332119A (en) | 1996-04-12 | 2001-08-31 | Warner Lambert Co | Quinazoline compounds which are irreversible inhibitors of tyrosine kinases |
DK0896544T3 (da) * | 1996-06-11 | 2003-05-05 | Novartis Ag | Kombination af en somatostatinanalog og en rapamycin |
ATE308527T1 (de) | 1996-06-24 | 2005-11-15 | Pfizer | Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten |
US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
CA2266039A1 (en) | 1996-09-09 | 1998-03-12 | Thomas Joseph Caggiano | Alkylated rapamycin derivatives |
DE19638745C2 (de) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
GB9619631D0 (en) * | 1996-09-20 | 1996-11-06 | British Biotech Pharm | Combination therapy |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
US5985325A (en) | 1997-06-13 | 1999-11-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6015815A (en) * | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6152347A (en) | 1998-01-30 | 2000-11-28 | Acco Brands, Inc. | Vertical Stapler |
ES2219000T3 (es) | 1998-03-26 | 2004-11-16 | Fujisawa Pharmaceutical Co., Ltd. | Preparacion de liberacion sostenida de un compuesto macrolido. |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
CN1161117C (zh) * | 1998-04-27 | 2004-08-11 | 藤泽药品工业株式会社 | 药物组合物 |
ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
IL143596A0 (en) | 1998-12-22 | 2002-04-21 | Genentech Inc | Vascular endothelial cell growth factor antagonists and uses thereof |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
WO2000059509A1 (en) | 1999-03-30 | 2000-10-12 | Novartis Ag | Phthalazine derivatives for treating inflammatory diseases |
US6333348B1 (en) * | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
GB9911582D0 (en) * | 1999-05-18 | 1999-07-21 | Pharmacia & Upjohn Spa | Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound |
EP1074265A1 (en) | 1999-08-03 | 2001-02-07 | Erasmus Universiteit Rotterdam | Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility |
CA2391319A1 (en) | 1999-08-18 | 2001-02-22 | American Home Products Corporation | Water soluble sdz-rad esters |
WO2001045740A2 (en) | 1999-12-22 | 2001-06-28 | The Government Of The United States, Department Of Health And Human Services | Compositions and methods for treatment of breast cancer |
US6899731B2 (en) * | 1999-12-30 | 2005-05-31 | Boston Scientific Scimed, Inc. | Controlled delivery of therapeutic agents by insertable medical devices |
EP1250135B1 (en) | 2000-01-14 | 2010-07-28 | The Trustees of The University of Pennsylvania | O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
US6641811B1 (en) * | 2000-02-10 | 2003-11-04 | Cornell Research Foundation, Inc. | Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression |
GB0005257D0 (en) | 2000-03-03 | 2000-04-26 | Pharmacia & Upjohn Spa | Breast cancer hormonal therapy |
US6761895B2 (en) | 2000-04-17 | 2004-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Drug delivery system for averting pharmacokinetic drug interaction and method thereof |
US20020013335A1 (en) * | 2000-06-16 | 2002-01-31 | American Home Products Corporation | Method of treating cardiovascular disease |
GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
ES2228932T3 (es) * | 2000-08-11 | 2005-04-16 | Wyeth | Procedimiento de tratamiento del carcinoma positivo de estrogenos. |
AU2001287157A1 (en) * | 2000-09-12 | 2002-03-26 | Virginia Commonwealth University | Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents |
WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
KR20030045847A (ko) | 2000-10-31 | 2003-06-11 | 쿡 인코포레이티드 | 코팅된 이식형 의료 장치 |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
JP2004523275A (ja) * | 2000-12-22 | 2004-08-05 | アバンテク バスキュラー コーポレーション | 治療能力のある薬剤の送達 |
US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
CN104274442A (zh) | 2001-02-19 | 2015-01-14 | 诺华股份有限公司 | 癌症的治疗 |
HUP0304093A3 (en) | 2001-04-06 | 2008-08-28 | Wyeth Corp | Antineoplastic combinations containing and mtor inhibitor and an antimetabolic antineoplastic agent and pharmaceutical compositions containing them |
IL158800A0 (en) * | 2001-06-01 | 2004-05-12 | Wyeth Corp | Antineoplastic combinations |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
US7488313B2 (en) | 2001-11-29 | 2009-02-10 | Boston Scientific Scimed, Inc. | Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment |
JP2003330447A (ja) | 2002-05-15 | 2003-11-19 | Mitsubishi Electric Corp | 画像処理装置 |
PL2275103T3 (pl) | 2005-11-21 | 2014-09-30 | Novartis Ag | Inhibitory mTOR w leczeniu nowotworów neuroendokrynnych |
RU2609458C2 (ru) | 2011-07-01 | 2017-02-01 | Колопласт А/С | Катетер с баллоном |
EP2606816A1 (en) | 2011-12-22 | 2013-06-26 | Koninklijke Philips Electronics N.V. | A method and system for providing an indication as to the amount of milk remaining in a breast during lactation |
-
2002
- 2002-02-18 CN CN201410469536.8A patent/CN104274442A/zh active Pending
- 2002-02-18 CN CN201410286316.1A patent/CN104116738A/zh active Pending
- 2002-02-18 ES ES16186041T patent/ES2705016T3/es not_active Expired - Lifetime
- 2002-02-18 PT PT141645655T patent/PT2762140T/pt unknown
- 2002-02-18 CZ CZ20032209A patent/CZ303611B6/cs not_active IP Right Cessation
- 2002-02-18 SK SK5011-2005A patent/SK288545B6/sk unknown
- 2002-02-18 RU RU2003127391/15A patent/RU2322981C2/ru active
- 2002-02-18 BR BR0207378-1A patent/BR0207378A/pt not_active Application Discontinuation
- 2002-02-18 PT PT181557224T patent/PT3345602T/pt unknown
- 2002-02-18 CN CNA028068440A patent/CN1551767A/zh active Pending
- 2002-02-18 HU HU0303271A patent/HUP0303271A3/hu not_active Application Discontinuation
- 2002-02-18 PL PL02363918A patent/PL363918A1/xx not_active IP Right Cessation
- 2002-02-18 DK DK18155644.0T patent/DK3351246T3/da active
- 2002-02-18 SI SI200231056T patent/SI2269603T1/sl unknown
- 2002-02-18 MX MXPA03007418A patent/MXPA03007418A/es active IP Right Grant
- 2002-02-18 DK DK16186041.6T patent/DK3143995T3/en active
- 2002-02-18 PT PT18155724T patent/PT3342411T/pt unknown
- 2002-02-18 EP EP10174985.1A patent/EP2269604B1/en not_active Revoked
- 2002-02-18 DK DK10174983.6T patent/DK2269603T3/en active
- 2002-02-18 KR KR1020057017585A patent/KR20050095906A/ko not_active Application Discontinuation
- 2002-02-18 PT PT16186041T patent/PT3143995T/pt unknown
- 2002-02-18 LT LTEP14164565.5T patent/LT2762140T/lt unknown
- 2002-02-18 EP EP18155722.4A patent/EP3345602B1/en not_active Expired - Lifetime
- 2002-02-18 DK DK10174985.1T patent/DK2269604T3/en active
- 2002-02-18 CN CNB2005100554588A patent/CN1296043C/zh not_active Ceased
- 2002-02-18 CA CA2438504A patent/CA2438504C/en not_active Expired - Lifetime
- 2002-02-18 EP EP02719864A patent/EP1363627A2/en not_active Withdrawn
- 2002-02-18 CZ CZ2019-248A patent/CZ309247B6/cs not_active IP Right Cessation
- 2002-02-18 ES ES18155722T patent/ES2921798T3/es not_active Expired - Lifetime
- 2002-02-18 SI SI200231097T patent/SI3342411T1/sl unknown
- 2002-02-18 EP EP14164561.4A patent/EP2764865A3/en not_active Withdrawn
- 2002-02-18 EP EP20100174983 patent/EP2269603B1/en not_active Revoked
- 2002-02-18 LT LTEP16186041.6T patent/LT3143995T/lt unknown
- 2002-02-18 KR KR1020077022986A patent/KR20070102762A/ko not_active Application Discontinuation
- 2002-02-18 ES ES14164565.5T patent/ES2629317T3/es not_active Expired - Lifetime
- 2002-02-18 PL PL415000A patent/PL415000A1/pl unknown
- 2002-02-18 CN CN201410286300.0A patent/CN104083365A/zh active Pending
- 2002-02-18 CZ CZ2005-91A patent/CZ200591A3/cs not_active IP Right Cessation
- 2002-02-18 DK DK14164565.5T patent/DK2762140T3/en active
- 2002-02-18 EP EP14164565.5A patent/EP2762140B1/en not_active Revoked
- 2002-02-18 KR KR1020037010870A patent/KR100695846B1/ko active IP Right Review Request
- 2002-02-18 US US10/468,520 patent/US8410131B2/en active Active
- 2002-02-18 SI SI200231088A patent/SI2762140T1/sl unknown
- 2002-02-18 SK SK902019A patent/SK288834B6/sk unknown
- 2002-02-18 LT LTEP18155644.0T patent/LT3351246T/lt unknown
- 2002-02-18 LT LTEP18155724.0T patent/LT3342411T/lt unknown
- 2002-02-18 SK SK50008-2016A patent/SK288630B6/sk unknown
- 2002-02-18 PT PT18155644T patent/PT3351246T/pt unknown
- 2002-02-18 WO PCT/EP2002/001714 patent/WO2002066019A2/en active Application Filing
- 2002-02-18 EP EP14164259.5A patent/EP2783686B1/en not_active Revoked
- 2002-02-18 SI SI200231092T patent/SI3143995T1/sl unknown
- 2002-02-18 CA CA2860306A patent/CA2860306C/en not_active Expired - Lifetime
- 2002-02-18 ES ES14164259.5T patent/ES2640787T3/es not_active Expired - Lifetime
- 2002-02-18 PT PT101749851T patent/PT2269604T/pt unknown
- 2002-02-18 EP EP18181342.9A patent/EP3406249A1/en not_active Withdrawn
- 2002-02-18 JP JP2002565579A patent/JP2004525899A/ja active Pending
- 2002-02-18 CA CA2994779A patent/CA2994779C/en not_active Expired - Lifetime
- 2002-02-18 EP EP18155644.0A patent/EP3351246B8/en not_active Revoked
- 2002-02-18 PT PT101749836T patent/PT2269603E/pt unknown
- 2002-02-18 SI SI200231094T patent/SI3351246T1/sl unknown
- 2002-02-18 CZ CZ2018211A patent/CZ309178B6/cs not_active IP Right Cessation
- 2002-02-18 DK DK18155724.0T patent/DK3342411T3/da active
- 2002-02-18 SK SK1038-2003A patent/SK288546B6/sk unknown
- 2002-02-18 ES ES18155644T patent/ES2728739T3/es not_active Expired - Lifetime
- 2002-02-18 ES ES10174985.1T patent/ES2600304T3/es not_active Expired - Lifetime
- 2002-02-18 SK SK50003-2016A patent/SK288524B6/sk unknown
- 2002-02-18 MX MX2014014346A patent/MX368013B/es unknown
- 2002-02-18 AU AU2002250968A patent/AU2002250968C1/en not_active Expired
- 2002-02-18 ES ES10174983.6T patent/ES2543383T3/es not_active Expired - Lifetime
- 2002-02-18 PL PL409579A patent/PL409579A1/pl unknown
- 2002-02-18 LT LTEP10174985.1T patent/LT2269604T/lt unknown
- 2002-02-18 PL PL414996A patent/PL231418B1/pl unknown
- 2002-02-18 NZ NZ527692A patent/NZ527692A/en not_active IP Right Cessation
- 2002-02-18 EP EP16186041.6A patent/EP3143995B1/en not_active Expired - Lifetime
- 2002-02-18 EP EP18155724.0A patent/EP3342411B1/en not_active Expired - Lifetime
- 2002-02-18 PL PL414997A patent/PL414997A1/pl unknown
- 2002-02-18 IL IL15742502A patent/IL157425A0/xx unknown
- 2002-02-18 CZ CZ2010-473A patent/CZ307940B6/cs not_active IP Right Cessation
- 2002-02-18 ES ES18155724T patent/ES2744377T3/es not_active Expired - Lifetime
- 2002-02-18 SI SI200231078A patent/SI2269604T1/sl unknown
- 2002-02-19 TW TW095103554A patent/TW200626151A/zh unknown
- 2002-02-19 TW TW091102797A patent/TWI334350B/zh not_active IP Right Cessation
-
2003
- 2003-08-14 IL IL157425A patent/IL157425A/en active IP Right Grant
- 2003-08-18 NO NO20033651A patent/NO333105B1/no not_active IP Right Cessation
- 2003-08-19 MX MX2019010879A patent/MX2019010879A/es unknown
-
2004
- 2004-04-15 HK HK11101880.8A patent/HK1146245A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK14110193.8A patent/HK1197723A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK18109752.9A patent/HK1250336B/zh not_active IP Right Cessation
- 2004-04-15 HK HK14112655.5A patent/HK1198946A1/xx not_active IP Right Cessation
- 2004-04-15 HK HK18109528.2A patent/HK1250019A1/zh not_active IP Right Cessation
- 2004-04-15 HK HK18109527.3A patent/HK1250018B/zh not_active IP Right Cessation
- 2004-04-15 HK HK11101882.6A patent/HK1146247A1/xx not_active IP Right Cessation
-
2005
- 2005-03-01 RU RU2005105664/15A patent/RU2325906C2/ru active
-
2006
- 2006-11-16 RU RU2006140514/15A patent/RU2445093C2/ru not_active IP Right Cessation
-
2007
- 2007-08-06 JP JP2007204409A patent/JP2007284454A/ja active Pending
-
2009
- 2009-11-16 IL IL202155A patent/IL202155A/en active IP Right Grant
-
2011
- 2011-09-22 RU RU2011138835/15A patent/RU2483727C1/ru active
-
2012
- 2012-02-23 US US13/403,474 patent/US20130059877A1/en not_active Abandoned
- 2012-02-23 US US13/403,578 patent/US8436010B2/en not_active Expired - Lifetime
- 2012-04-18 NO NO20120451A patent/NO335134B1/no not_active IP Right Cessation
- 2012-04-26 JP JP2012101519A patent/JP5775022B2/ja not_active Expired - Lifetime
- 2012-05-31 IL IL220096A patent/IL220096A/en active IP Right Grant
- 2012-05-31 IL IL220095A patent/IL220095A/en active IP Right Grant
- 2012-07-11 US US13/546,686 patent/US8778962B2/en not_active Expired - Lifetime
-
2013
- 2013-01-09 NO NO20130045A patent/NO334646B1/no not_active IP Right Cessation
- 2013-04-26 RU RU2013119705A patent/RU2665138C2/ru active
- 2013-05-14 US US13/893,537 patent/US20130253000A1/en not_active Abandoned
- 2013-05-14 US US13/893,589 patent/US20130244951A1/en not_active Abandoned
- 2013-06-27 US US13/928,891 patent/US8877771B2/en not_active Expired - Fee Related
- 2013-06-27 US US13/928,583 patent/US20130296359A1/en not_active Abandoned
- 2013-09-24 RU RU2013143306A patent/RU2659725C2/ru active
- 2013-10-30 IL IL229159A patent/IL229159A0/en unknown
- 2013-10-30 IL IL229160A patent/IL229160B/en active IP Right Grant
- 2013-10-30 IL IL229156A patent/IL229156A/en active IP Right Grant
- 2013-10-30 IL IL229157A patent/IL229157A0/en unknown
- 2013-10-30 IL IL229158A patent/IL229158A/en active IP Right Grant
- 2013-11-19 NO NO20131547A patent/NO336581B1/no not_active IP Right Cessation
- 2013-11-19 NO NO20131546A patent/NO336110B1/no not_active IP Right Cessation
- 2013-11-19 NO NO20131545A patent/NO336428B1/no not_active Application Discontinuation
- 2013-11-19 NO NO20131544A patent/NO336208B1/no not_active IP Right Cessation
- 2013-12-19 US US14/134,419 patent/US20140105895A1/en not_active Abandoned
-
2014
- 2014-05-02 JP JP2014095034A patent/JP5873128B2/ja not_active Expired - Lifetime
- 2014-06-02 JP JP2014114297A patent/JP5879391B2/ja not_active Expired - Lifetime
- 2014-06-02 JP JP2014114296A patent/JP2014208657A/ja not_active Withdrawn
-
2015
- 2015-03-18 NO NO2015010C patent/NO2015010I1/no unknown
- 2015-04-08 JP JP2015079430A patent/JP6333766B2/ja not_active Expired - Lifetime
- 2015-04-09 NO NO20150413A patent/NO20150413L/no not_active Application Discontinuation
- 2015-06-24 NO NO20150831A patent/NO340553B1/no not_active IP Right Cessation
- 2015-07-08 NO NO20150895A patent/NO339240B1/no not_active IP Right Cessation
- 2015-08-13 CY CY20151100711T patent/CY1116616T1/el unknown
- 2015-11-17 LU LU92880C patent/LU92880I2/xx unknown
- 2015-11-19 CY CY2015044C patent/CY2015044I1/el unknown
-
2016
- 2016-06-28 US US15/195,018 patent/US20160303092A1/en not_active Abandoned
- 2016-07-29 JP JP2016149701A patent/JP6310970B2/ja not_active Expired - Lifetime
- 2016-08-24 NO NO20161348A patent/NO340924B1/no not_active IP Right Cessation
- 2016-10-21 CY CY20161101060T patent/CY1118316T1/el unknown
- 2016-11-23 LU LU93320C patent/LU93320I2/fr unknown
- 2016-11-28 LT LTPA2016035C patent/LTC2269604I2/lt unknown
- 2016-12-20 CY CY2016047C patent/CY2016047I2/el unknown
-
2017
- 2017-01-06 JP JP2017001065A patent/JP6383814B2/ja not_active Expired - Lifetime
- 2017-02-20 IL IL250676A patent/IL250676B/en active IP Right Grant
- 2017-03-19 IL IL251270A patent/IL251270B/en active IP Right Grant
- 2017-05-16 NO NO20170803A patent/NO343599B1/no not_active IP Right Cessation
- 2017-06-22 CY CY20171100668T patent/CY1119029T1/el unknown
-
2018
- 2018-02-08 JP JP2018021354A patent/JP6349476B2/ja not_active Expired - Lifetime
- 2018-02-08 JP JP2018021353A patent/JP6349475B2/ja not_active Expired - Lifetime
- 2018-02-08 JP JP2018021352A patent/JP6349474B2/ja not_active Expired - Lifetime
- 2018-05-31 IL IL259724A patent/IL259724B/en unknown
- 2018-06-08 RU RU2018121314A patent/RU2018121314A/ru not_active Application Discontinuation
- 2018-07-06 JP JP2018129096A patent/JP2018168188A/ja not_active Withdrawn
- 2018-07-30 RU RU2018127821A patent/RU2018127821A/ru not_active Application Discontinuation
-
2019
- 2019-01-10 CY CY20191100021T patent/CY1121314T1/el unknown
- 2019-03-04 NO NO20190290A patent/NO20190290A1/no not_active Application Discontinuation
- 2019-06-04 LU LU00122C patent/LUC00122I2/fr unknown
- 2019-06-04 CY CY2019030C patent/CY2019030I2/el unknown
- 2019-06-04 LT LTPA2019511C patent/LTPA2019511I1/lt unknown
- 2019-06-14 CY CY20191100619T patent/CY1121715T1/el unknown
- 2019-09-03 CY CY20191100925T patent/CY1121983T1/el unknown
- 2019-11-21 CY CY2019043C patent/CY2019043I1/el unknown
- 2019-11-21 LT LTPA2019521 patent/LTPA2019521I1/lt unknown
-
2020
- 2020-02-20 CY CY2020005C patent/CY2020005I1/el unknown
- 2020-02-20 LT LTPA2020503C patent/LTPA2020503I1/lt unknown
- 2020-05-26 JP JP2020091227A patent/JP6904640B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3342411T (pt) | Derivados da rapamicina para tratamento do cancro do pâncreas | |
AU2003232882A8 (en) | Prostacyclin derivatives for treating cancer | |
AU2002324574A1 (en) | Methods for treating prostatitis | |
AU2002303283A1 (en) | Methods for treating drug addiction | |
PL371192A1 (en) | Polymer derivatives for treating metals | |
IL160208A0 (en) | Amidine derivatives for treating amyloidosis | |
IL164352A0 (en) | Methods for treating tweak-related conditions | |
EP1680073A4 (en) | COMPOUNDS AND METHOD OF TREATING CANCER | |
AU2002225930A1 (en) | Methods for treating phosphatide-containing mixtures | |
EP1687322A4 (en) | ADAPTED VECTORS FOR THE TREATMENT AND PREVENTION OF PANCREATIC CANCER | |
EP1401377A4 (en) | CANCER TREATMENT METHODS | |
IL168059A0 (en) | Benzopyranone compounds, compositions thereof, and methods for treating orpreventing cancer | |
GB0322773D0 (en) | The method of treating cancer | |
PT1400522E (pt) | Compostos para tratar a impotência | |
AU2002323774A1 (en) | New compounds for treating impotence | |
GB0223325D0 (en) | Treating cancer | |
AU2003298534A1 (en) | Method for treating cancer | |
AU2002336130A1 (en) | Pyridin-2-YL-Methlyamine derivatives for treating opioid dependence | |
AU2002360454A8 (en) | Methods and compositions for treating cancer | |
HK1053108A1 (en) | New compounds for treating impotence | |
GB0130824D0 (en) | Method for cancer treatment | |
IL145144A0 (en) | Ointment for treating pains | |
GB0216634D0 (en) | Treating cancer | |
AU2002326977A1 (en) | Methods for treating and preventing migraines | |
AUPR950401A0 (en) | Methods for treatment |